About
Focus
Pipeline
Patients
Investors
Company Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Governance
SEC Filings
Investor FAQs
Careers
About
Focus
Pipeline
Patients
Investors
Company Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Governance
SEC Filings
Investor FAQs
Careers
The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
The Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
November 2018
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Tumor Inflammatory Status in the Microenvironment of Melanoma
© 2023 X4 Pharmaceuticals, Inc. All rights reserved.
Terms of Use
|
Privacy Policy